RT Journal Article
SR Electronic
T1 The effect of influenza vaccination on trained immunity: impact on COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.14.20212498
DO 10.1101/2020.10.14.20212498
A1 Debisarun, Priya A.
A1 Struycken, Patrick
A1 Domínguez-Andrés, Jorge
A1 Moorlag, Simone J.C.F.M.
A1 Taks, Esther
A1 Gössling, Katharina L.
A1 Ostermann, Philipp N.
A1 Müller, Lisa
A1 Schaal, Heiner
A1 Oever, Jaap ten
A1 van Crevel, Reinout
A1 Netea, Mihai G.
YR 2020
UL http://medrxiv.org/content/early/2020/10/16/2020.10.14.20212498.abstract
AB Every year, influenza causes 290.000 to 650.000 deaths worldwide and vaccination is encouraged to prevent infection in high-risk individuals. Interestingly, cross-protective effects of vaccination against heterologous infections have been reported, and long-term boosting of innate immunity (also termed trained immunity) has been proposed as the underlying mechanism. Several epidemiological studies also suggested cross-protection between influenza vaccination and COVID-19 during the current pandemic. However, the mechanism behind such an effect is unknown. Using an established in-vitro model of trained immunity, we demonstrate that the quadrivalent inactivated influenza vaccine used in the Netherlands in the 2019-2020 influenza season can induce a trained immunity response, including an improvement of cytokine responses after stimulation of human immune cells with SARS-CoV-2. In addition, we found that SARS-CoV-2 infection was less common among Dutch hospital employees who had received influenza vaccination during the 2019/2020 winter season (RR = 0,61 (95% CI, 0.4585 - 0.8195, P = 0.001). In conclusion, a quadrivalent inactivated influenza vaccine can induce trained immunity responses against SARS-CoV-2, which may result in relative protection against COVID-19. These data, coupled with similar recent independent reports, argue for a beneficial effect of influenza vaccination against influenza as well as COVID-19, and suggests its effective deployment in the 2020-2021 influenza season to protect against both infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMGN was supported by a Spinoza Grant of the Netherlands Association for Scientific Research and an ERC Advanced Grant (no. 833247). PNO, LM and HS were supported by the Jurgen Manchot Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CMO regio Arnhem- NijmegenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.